Register now to R3i !
Your Login
Your Password
Confirm Password  
Your Email
I agree to receive
the R3i newsletter



CNIC polypill improves atherogenic dyslipidaemia in a real-world primary prevention setting

Atherogenic dyslipidaemia, characterised by elevated triglycerides and low plasma levels of high-density lipoprotein cholesterol (HDL-C), is implicated as a contributor to lipid-related residual cardiovascular risk. This post hoc analysis of high-risk primary prevention patients in Mexico showed that the CNIC (Centro Nacional de Investigaciones Cardiovasculares) polypill, a fixed dose combination of aspirin, the ACE-inhibitor ramipril and simvastatin, also favourably impacted atherogenic dyslipidaemia in this group.  
In total, 533 patients included in a prospective registry were evaluated for blood lipids at baseline (usual care) and after 12 months of treatment with the CNIC-polypill. After one year of treatment, there were significant reductions (p<0.001) in levels of total cholesterol (by 22%), triglycerides (by 29%), and non-HDL-C (by 29%) (all p < 0.001). In addition, atherogenic dyslipidaemia-related ratios including remnant cholesterol and the atherogenic index, were also significantly lower with the polypill treatment. Moreover, patients were seven-fold more likely to attain desirable TG levels with this treatment, given in a real-world primary prevention setting.
The CNIC-polypill improves atherogenic dyslipidemia markers in patients at high risk or with cardiovascular disease: Results from a real-world setting in Mexico.

Gómez-Álvarez E, Verdejo J, Ocampo S, et al.